Key result
Higher Postdose 3 G1 serum neutralizing antibody titers were associated with lower odds of contracting rotavirus gastroenteritis and correlated most closely with vaccine efficacy.
Why the study?
Do Postdose 3 G1 serum neutralizing antibody titers correlate with protection against rotavirus gastroenteritis after pentavalent rotavirus vaccination?
Meta-Analysis
Yes
Do Postdose 3 G1 serum neutralizing antibody titers correlate with protection against rotavirus gastroenteritis after pentavalent rotavirus vaccination?
Postdose 3 G1 serum neutralizing antibody titers correlate closely with rotavirus gastroenteritis risk and vaccine efficacy, serving as a potential correlate of protection for the pentavalent rotavirus vaccine.
Answers are grounded in this paper and cite their sources.
Pooled RV5 SNA and IgA data may guide correlate searches; leaves open validated protection thresholds.
Although clinical trials of the pentavalent rotavirus vaccine (RotaTeq®, RV5) have demonstrated efficacy against RV gastroenteritis (RGE) in low and high-income settings, a clear correlate of protection or a measure of immune response that could predict efficacy has yet to be identified. This is the first time that immunogenicity data with both serum neutralized antibody (SNA) titers and anti-RV IgA titers from several clinical efficacy trials were pooled to provide a unique context for evaluating the correlation between immunogenicity and RGE risk or efficacy of RV5. The correlation between immunogenicity and RGE risk is evaluated with data at the individual subject level. The analyses show that higher Postdose 3 (PD3) G1 SNA titers are associated with lower odds of contracting any RGE. The correlation between immunogenicity and efficacy is assessed using aggregated population level data, which shows higher efficacy associated with higher PD3 G1 SNA geometric mean titer (GMT) ratio (between RV5 and placebo) and PD3 serum anti-RV IgA GMT ratio. Among high-income countries, efficacy plateaus over the range of PD3 G1 SNA GMT ratios and PD3 serum anti-RV IgA GMT ratios. From both individual- and population-level analyses, PD3 G1 SNA titers correlated most closely with the RGE risk or efficacy for RV5.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) conducted a meta-analysis in Rotavirus gastroenteritis. Pentavalent rotavirus vaccine (RotaTeq, RV5) vs. Placebo was evaluated on Rotavirus gastroenteritis (RGE) risk and vaccine efficacy. Higher Postdose 3 G1 serum neutralizing antibody titers were associated with lower odds of contracting rotavirus gastroenteritis and correlated most closely with vaccine efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: